About FIB-4 Calculator
7 min read
FIB-4 Calculator: Estimate Liver Fibrosis Risk From Simple Blood Tests
TL;DR: Enter your age, AST, ALT, and platelet count, and this calculator returns your FIB-4 index in seconds. A score below 1.30 suggests low risk of advanced fibrosis (F0-F1). Scores between 1.30 and 2.67 fall into an indeterminate zone that warrants further testing. Above 2.67 signals high risk of advanced fibrosis (F3-F4). For patients over 65, the low-risk cutoff shifts upward to 2.0. Originally validated in hepatitis C cohorts (Sterling et al., 2006), FIB-4 now sees routine use in fatty liver disease screening.
Table of Contents
- A Blood Test That Replaces a Needle in the Liver
- Six Situations Where Your FIB-4 Score Changes What Happens Next
- How the FIB-4 Formula Works
- From Lab Report to FIB-4 Score: Step by Step
- See How the Numbers Play Out: Two Real-World Examples
- Six Errors That Distort Your FIB-4 Results
- FAQ
- Assumptions and Notes
- Your Next Step
- Further Reading
A Blood Test That Replaces a Needle in the Liver
Liver biopsy has been the gold standard for staging fibrosis for decades, but it is invasive, expensive, and carries a 1-in-500 risk of serious complications. Most patients with chronic liver disease never receive one. That gap between clinical need and practical reality is where FIB-4 fits in.
FIB-4 (Fibrosis-4 Index) is a non-invasive scoring system that estimates the degree of liver scarring using four values already sitting on a standard blood panel: age, AST, ALT, and platelet count. Sterling et al. published the original validation in 2006 using a cohort of 832 patients co-infected with HIV and hepatitis C. Since then, large-scale studies have confirmed its accuracy in non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and chronic hepatitis B. The index carries a negative predictive value above 90% for ruling out advanced fibrosis when the score falls below the low-risk cutoff.
The biological mechanism is straightforward. As fibrosis progresses, damaged hepatocytes leak more AST into the bloodstream. Simultaneously, the scarred liver traps and destroys platelets at a higher rate, dropping the platelet count. Age amplifies both effects because cumulative exposure to the injuring agent (alcohol, fat, virus) increases fibrosis severity over time. ALT in the denominator adjusts for active inflammation that would inflate AST independently of scarring.
Plug your four lab values into the calculator above and get your score before the next paragraph.
Six Situations Where Your FIB-4 Score Changes What Happens Next
-
Routine NAFLD screening after abnormal liver enzymes. About 25% of the global adult population has some degree of fatty liver. If an ultrasound flags steatosis and your AST or ALT runs above 40 U/L, calculating FIB-4 takes 10 seconds and determines whether you need a referral to hepatology or can safely monitor with repeat labs in 6 to 12 months.
-
Monitoring chronic hepatitis B or C between imaging appointments. Patients on antiviral therapy for hepatitis typically undergo elastography or biopsy every 1 to 2 years. FIB-4 fills the intervals: a score that drops from 2.8 to 1.5 over 18 months of treatment confirms fibrosis regression without scheduling another procedure.
-
Evaluating liver risk before starting hepatotoxic medication. Methotrexate, amiodarone, and certain antiretrovirals carry known liver toxicity profiles. A baseline FIB-4 below 1.30 before starting treatment and a recheck at 6 months gives prescribers a quantitative safety signal. A jump of 0.5 points or more triggers closer monitoring.
-
Assessing liver health in patients with type 2 diabetes. Up to 70% of type 2 diabetics have concurrent NAFLD, and about 12% progress to non-alcoholic steatohepatitis (NASH) with fibrosis. Running FIB-4 at annual diabetic reviews catches progression early, when lifestyle interventions still reverse the trajectory.
-
Screening heavy alcohol users who refuse imaging. Patients consuming more than 14 standard drinks per week for over 5 years have significantly elevated fibrosis risk. Some decline further testing. FIB-4 requires only the blood work they already agreed to, and a score above 2.67 creates a concrete, numbers-driven conversation about next steps.
-
Triaging gastroenterology referrals in primary care. Specialist wait times for hepatology average 60 to 90 days in many health systems. A FIB-4 score below 1.30 lets primary care physicians safely defer the referral and recheck in a year, reserving specialist slots for patients whose scores land in the indeterminate or high-risk range.
How the FIB-4 Formula Works
The formula combines four routine lab values into a single index that correlates with histological fibrosis stage.
FIB-4 = (Age × AST) / (Platelets × √ALT)
| Variable | Unit | Role in the Formula |
|---|---|---|
| Age | Years | Proxy for cumulative liver exposure |
| AST | U/L | Rises with hepatocyte damage and fibrosis |
| ALT | U/L | Adjusts for inflammation vs. scarring |
| Platelets | ×10⁹/L | Drops as the fibrotic liver sequesters them |
FIB-4 Risk Thresholds
| Score Range | Risk Category | Fibrosis Stage | Recommended Action |
|---|---|---|---|
| < 1.30 | Low risk | F0-F1 | Reassess in 1-2 years |
| 1.30 – 2.67 | Indeterminate | Possible F2-F3 | Further testing (elastography, ELF, biopsy) |
| > 2.67 | High risk | F3-F4 (advanced) | Hepatology referral |
Age-Adjusted Cutoffs (Over 65)
| Score Range | Risk Category | Action |
|---|---|---|
| < 2.0 | Low risk | Monitor, repeat annually |
| ≥ 2.0 | Elevated risk | Further evaluation recommended |
Standard cutoffs misclassify up to 30% of patients over 65 as indeterminate or high-risk simply because age inflates the numerator. The adjusted thresholds published by McPherson et al. (2017) reduce unnecessary referrals in older populations by nearly half.
Genetic and population variation. Carriers of the PNPLA3 I148M variant, common in Hispanic populations, develop fibrosis at lower levels of liver fat than non-carriers. Their FIB-4 scores may underestimate true fibrosis stage because ALT and AST elevations can be modest relative to the histological damage. Clinicians should interpret FIB-4 alongside genetic risk factors when available.
Limitations. FIB-4 performs best at the extremes: ruling out advanced fibrosis (below 1.30) or confirming high probability (above 2.67). The indeterminate zone captures roughly 30 to 50% of patients, and those individuals need a second-line test such as transient elastography (FibroScan) or the Enhanced Liver Fibrosis (ELF) panel to resolve their staging.
From Lab Report to FIB-4 Score: Step by Step
-
Collect your lab results. You need four values from a standard liver panel and complete blood count: age, AST (U/L), ALT (U/L), and platelet count (×10⁹/L). Most labs report platelets as a raw number like 200, meaning 200 × 10⁹/L.
-
Confirm the platelet unit. Some labs report platelets in thousands per microliter (e.g., 200 K/µL). This is numerically identical to 200 × 10⁹/L. If your report shows a value like 200,000 without the "K" notation, divide by 1,000 before entering it.
-
Check timing. AST and ALT fluctuate with acute illness, alcohol intake in the prior 48 hours, and intense exercise. Results drawn during an acute hepatitis flare will inflate your FIB-4 and overestimate fibrosis. Wait at least 2 weeks after an acute episode to get a reliable baseline.
-
Enter all four values into the calculator. Input age in years, AST in U/L, ALT in U/L, and platelet count.
-
Read your FIB-4 score. The calculator returns the numeric index and an interpretation band (low, indeterminate, or high risk).
-
Apply age-adjusted cutoffs if you are over 65. The standard low-risk cutoff of 1.30 rises to 2.0 for patients older than 65. The calculator notes this automatically, but confirm you are reading the correct threshold.
-
Decide on next steps with your clinician. A low-risk score means monitoring. An indeterminate score means a second-line test. A high-risk score means referral. One non-obvious insight: serial FIB-4 trending (calculating every 6 to 12 months) is more informative than any single value, because a rising trajectory catches progression before the score crosses a threshold.
See How the Numbers Play Out: Two Real-World Examples
Example 1: 42-Year-Old Software Developer With Fatty Liver
A 42-year-old man was told his ultrasound shows mild hepatic steatosis. His recent lab work: AST 30 U/L, ALT 45 U/L, platelets 240 × 10⁹/L. He wants to know if he needs a liver biopsy.
Calculation:
FIB-4 = (42 × 30) / (240 × √45)
= 1260 / (240 × 6.708)
= 1260 / 1609.97
= 0.78
| Parameter | Value | Unit |
|---|---|---|
| Age | 42 | years |
| AST | 30 | U/L |
| ALT | 45 | U/L |
| Platelets | 240 | ×10⁹/L |
| FIB-4 Score | 0.78 | — |
Interpretation: 0.78 falls well below the 1.30 low-risk cutoff. Advanced fibrosis is unlikely (negative predictive value > 90%). His physician can recommend dietary changes, a 7 to 10% body weight reduction target, and repeat blood work in 12 months. No biopsy or elastography needed at this stage.
Example 2: 68-Year-Old Retiree With Chronic Hepatitis C History
A 68-year-old woman completed antiviral therapy for hepatitis C three years ago and achieved sustained virologic response. Her follow-up labs: AST 38 U/L, ALT 28 U/L, platelets 155 × 10⁹/L. She wants to know her current fibrosis risk.
Calculation:
FIB-4 = (68 × 38) / (155 × √28)
= 2584 / (155 × 5.292)
= 2584 / 820.21
= 3.15
| Parameter | Value | Unit |
|---|---|---|
| Age | 68 | years |
| AST | 38 | U/L |
| ALT | 28 | U/L |
| Platelets | 155 | ×10⁹/L |
| FIB-4 Score | 3.15 | — |
Interpretation: At 3.15, the score exceeds both the standard high-risk threshold of 2.67 and the age-adjusted cutoff of 2.0 for patients over 65. Despite viral cure, residual fibrosis is likely. Her physician should order transient elastography to confirm fibrosis stage and consider hepatocellular carcinoma surveillance (ultrasound every 6 months) if staging confirms F3 or F4.
Six Errors That Distort Your FIB-4 Results
Using labs drawn during an acute illness. Viral gastroenteritis, influenza, or any systemic infection can spike AST by 2 to 5 times its baseline. A transient AST of 80 U/L in a 55-year-old with platelets of 180 and ALT of 35 produces a FIB-4 of 3.71, falsely placing them in the high-risk category. Wait at least two weeks after recovery before calculating.
Forgetting the age-adjusted cutoffs for patients over 65. The standard 1.30 low-risk threshold misclassifies approximately 30% of older adults as indeterminate. A 70-year-old with a score of 1.8 is still in the low-risk category under the McPherson age-adjusted framework. Always check which cutoff applies.
Entering platelets in the wrong unit. If your lab report reads "200,000/µL" and you enter 200,000 instead of 200 into the calculator, the result will be off by a factor of 1,000. The correct entry format is the value in thousands: 200, not 200,000. This single error is the most common cause of wildly inaccurate scores.
Ignoring recent alcohol intake. Drinking more than 4 standard drinks within 48 hours of the blood draw raises AST disproportionately to ALT, because alcohol metabolism directly damages mitochondria in hepatocytes. An AST/ALT ratio above 2.0 from acute alcohol use inflates FIB-4 by 0.5 to 1.5 points above the patient's true baseline. Abstain for at least 48 hours before the blood draw.
Relying on a single FIB-4 measurement for clinical decisions. Biological variation in AST, ALT, and platelets means day-to-day fluctuations of 10 to 15% are normal. A single score of 1.35 does not confirm indeterminate risk. Repeat the calculation with labs drawn 3 to 6 months apart and look at the trend. Two consecutive values below 1.30 are far more reassuring than one borderline result.
Applying FIB-4 in populations where it was not validated. The original Sterling cohort excluded patients under 35 and those with extrahepatic causes of low platelets (e.g., immune thrombocytopenia, bone marrow disorders). Using FIB-4 in a 25-year-old or a patient on chemotherapy with platelets of 80 from marrow suppression produces a misleadingly high score. Confirm that the platelet count reflects liver-related changes before interpreting the result.
Assumptions and Notes
- Margin of error. FIB-4 carries a negative predictive value above 90% for scores below 1.30 and a positive predictive value of approximately 65% for scores above 2.67. The indeterminate zone (1.30 to 2.67) requires second-line testing to resolve, and roughly 30 to 50% of patients fall into this range.
- Professional disclaimer. This calculator is an informational screening tool. It does not replace clinical evaluation, imaging, or liver biopsy. Discuss your results with a hepatologist or gastroenterologist, particularly if your score falls in the indeterminate or high-risk range.
Your Next Step
The formula takes four numbers you probably already have on your last lab report. If your score lands below 1.30, file it away and recheck in a year. If it sits in the indeterminate zone or above, book the follow-up test your doctor recommends and do not wait for symptoms. Liver fibrosis progresses silently for years, and the entire point of a screening index is to act before it announces itself.